3 Best Stocks to Buy Now, 10/21/2024, According to Top Analysts 
Market News

3 Best Stocks to Buy Now, 10/21/2024, According to Top Analysts 

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating recently and has a significant upside as well.

To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts. 

Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio. 

Cadence Design (CDNS) – This technology company provides electronic design automation (EDA) software and services for developing advanced semiconductor products. Today, KeyBanc analyst Jason Celino maintained a Buy rating on the stock. In the last three months, five out of the six Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 25%.

Ideaya Biosciences (IDYA) – This biotechnology company develops precision medicines for oncology based on synthetic lethality and immuno-oncology. Today, J.P. Morgan analyst Anupam Rama reiterated a Buy rating on the stock. In the last three months, all five Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 96%.

Ascendis Pharma (ASND) – Ascendis develops drugs for endocrinology and oncology indications. Today, TD Cowen analyst Yaron Werber reiterated a Buy rating on the stock with a price target of $160. In the last three months, all nine Top Analysts covering the stock have rated it a Buy. Altogether, their 12-month price targets imply an upside of about 54%.

Who Are the Top Analysts? 

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time. 

See real-time analyst rankings and learn more about the performance of Top Analysts on TipRanks’ Top Wall Street Analysts page. 

Disclosure 

Related Articles
TheFlyAscendis Pharma price target lowered to $174 from $180 at JPMorgan
TheFlyAscendis Pharma price target raised to $160 from $157 at TD Cowen
Go Ad-Free with Our App